Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
about
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancerProlonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neuTrastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancerThe origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesionsPrognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cellsNext-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situMMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancerTumour markers in breast carcinoma correlate with grade rather than with invasivenessDuctal carcinoma in situ of the breast: a surgical perspective.Minimal breast cancer: evaluation of histology and biological marker expression.Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.Signal transduction in mammary tumorigenesis: a transgenic perspective.The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer.Transgenic mouse models of human breast cancer.Oncogenes and tumor suppressor genesThe polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer.Current management of ductal carcinoma in situHER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target.Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer.MTA1--a stress response protein: a master regulator of gene expression and cancer cell behavior.Elevated transcription of the gene QSOX1 encoding quiescin Q6 sulfhydryl oxidase 1 in breast cancer.Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides.Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patientsCCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast.HER2: biology, detection, and clinical implicationsProtein identification from dried nipple aspirate fluid on Guthrie cards using mass spectrometry.Molecular analysis of premalignant and carcinoma in situ lesions of the human breast.Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expressionPrecursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.Intraductal proliferative lesions of the breast-terminology and biology matter: premalignant lesions or preinvasive cancer?Critical determination of the frequency of c-erbB-2 amplification in breast cancer.Pathological and biological features of mammographically detected invasive breast carcinomasc-erbB-3 protein expression in ovarian tumours.Prognostic factors for breast cancer and their use in the clinical setting.
P2860
Q24535378-53E0227D-3D78-4D18-A34C-52F06B907DE4Q24685875-C45F4C8A-57D9-4CD1-A8EE-FF807A189A88Q24795614-BC75DD93-3AE2-4CF2-B0ED-BA5401336481Q24796156-88C9AE26-373C-4177-8E39-18B6D54C44B9Q24802857-B018AAD5-2FD7-4003-B85A-0D7F9F13695AQ24812583-289EC3E9-9DDE-4297-A746-4922DD5EFE30Q25257668-928A8784-CAA2-401D-95CB-09FD246E502FQ26864448-3E036B26-79CF-42B4-9B2A-6E06E8C98FE3Q28250940-964593F8-888D-4141-9418-DA3684FC469DQ28352534-3CCF999C-512E-4068-8EEA-B2124833D928Q30463534-601AD9E6-19FC-4CA2-90DF-AF9BD985B83EQ33688620-9F7F5F65-5BA8-414E-BC12-CEEABAC0B605Q33767497-814E287F-26F2-40FD-8BDC-C61ECD22BAD1Q33801908-A31FBB97-5DBD-43FD-9C78-3BC5A1EEFC8BQ33860827-9B688FDF-0025-43F4-B695-071C3AE5DFEEQ34115095-5728A9DD-8190-422C-A649-C2177D175946Q34130558-A720D5F1-61EC-4171-8AA1-359127846AC6Q34149922-09EBA5D1-405B-439F-BD28-E730764ADC4BQ34169188-68D5181F-04C1-4826-958B-D1584741ECAEQ34182059-3C51AABB-30B6-4275-926B-0254AC45CF96Q34324291-E2352EF2-E5A6-49A2-BC40-729BBED827D9Q34510318-937CE8E4-5BF7-4F70-A76A-BEC597999784Q34535370-F24EF369-DFE5-41C3-80D5-F4BF9E1512F3Q34548277-5B3E78D2-FCC7-47F9-99E9-60AB0E17EC79Q34573808-47495599-F784-48BB-B2BF-1509387BCC61Q34608490-EEB740D9-BA01-4EDB-8F17-702041820D09Q34618574-B55DC5C8-ACFD-483B-9938-508C21746577Q34769976-EE53B067-A155-4BD4-859F-A38DC60EA730Q34983912-2E074D5D-9DBC-4817-9FB0-B15EFADBCB46Q35184326-49611C38-058E-44F5-933F-B8E509471D17Q35622862-1E5F33B8-68A0-4428-BDAC-16FFF1C1836CQ35628469-AFD7FC4E-17AB-4306-B0C3-7AFF130BE89FQ35782037-20194B14-4663-4E3F-A447-E4F671531599Q35786712-58A6D5F3-7C7B-43CD-BB79-6A7D78594C49Q35846896-F41DD0AE-32A2-476B-B151-88593E82241EQ35979090-D2B7D998-3447-4149-888F-469ABB1B831EQ36079541-284243E2-347E-4BE9-A7B7-0B2120E4D627Q36079849-BEE45D57-F87A-4F3F-9317-0D8D2A1B577EQ36080809-AB38834E-175F-403B-AD41-FE7A28DF7FF1Q36118398-874C1A6B-4404-40A0-B1FA-BB1AE9DD55C6
P2860
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Overexpression of HER-2/neu an ...... itu to invasive breast cancer.
@en
type
label
Overexpression of HER-2/neu an ...... itu to invasive breast cancer.
@en
prefLabel
Overexpression of HER-2/neu an ...... itu to invasive breast cancer.
@en
P2093
P1433
P1476
Overexpression of HER-2/neu an ...... itu to invasive breast cancer.
@en
P2093
Gilchrist KW
McGuire WL
Osborne CK
Schnitt SJ
P304
P356
10.1016/0046-8177(92)90257-4
P407
P577
1992-09-01T00:00:00Z